New gene therapy CME activity: The Science of Gene Therapy for Hemophilia

The World Federation of Hemophilia (WFH) is proud to announce the launch of the next activity in Clinical Advances in Gene Therapy for Hemophilia, an online continuing medical education (CME) program developed in collaboration with the National Hemophilia Foundation, the European Haemophilia Consortium and Medscape Education. The program is designed for clinicians but is available to everyone.

The program of five activities covers important information on the science behind gene therapy for hemophilia, the latest safety and efficacy data from clinical trials and the potential role for gene therapy in addressing the challenges of current treatment options. Clinicians can qualify for CME credits for each activity, and all learners can obtain a completion certificate, or simply use the program to enhance their knowledge of gene therapy in hemophilia.

The Science of Gene Therapy for Hemophilia
Glenn Pierce, MD
0.25 CME/ABIM MOC. Released August 3, 2018 and valid for credit through August 3, 2019.

The Science of Gene Therapy for Hemophilia is an expert video commentary on the vector technology behind gene therapy in hemophilia. Watch as Glenn Pierce, WFH Vice President, Medical, examines early clinical trials, the challenges and breakthroughs in vector design and emerging approaches to gene therapy in hemophilia. A transcript of the discussion in Activity #3 as well as presentation slides containing useful illustrations, key messages and pivotal gene therapy clinical trial data enhance the learner’s comprehension of this fascinating advanced content.

Learners are encouraged to study Activity #1 Test Your Knowledge of Gene Therapy in Hemophilia and Activity #2 Gene Therapy: Past, Present, and Future, prior to Activity #3, in order to get the most out of this specialist presentation.

Other activities coming soon in this curriculum include expert videos on the challenges of current therapies, as well as a clinical article describing recent advances in hemophilia gene therapy trials. Check back often as the two remaining activities will go live over the coming months!

To learn about Activity #1 and Activity #2, please click here.